Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Not yet enrolling

Phase 2

Conditions

Abdominal Neoplasm

Retroperitoneal Lymph Node Metastasis

Extended Lymphadenectomy

Retroperitoneal Lymphadenectomy

Pelvic Neoplasms

Chylous Ascites

Treatments

Drug: oral iohexol

Procedure: Lymphangiography and Embolization

Study type

Interventional

Funder types

Other

Identifiers

NCT06820320

No, 24/368-4648

Details and patient eligibility

About

The goal of this clinical trial is to assess the effectiveness of oral iohexol in the treatment of postoperative chylous ascites. It will also learn about the safety of oral iohexol. The main questions it aims to answer are:

Confirm the potential of oral iohexol as an innovative therapeutic regimen.
Confirm its ability to improve clinical outcomes for patients.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients between the ages of 18 and 75 years;
Patients underwent retroperitoneal or extended lymphadenectomy for abdominal or pelvic malignant tumors;
Patients diagnosisted with postoperative Chylous ascites. Chylous ascites were defined by the presence of non-infectious, milky, or creamy effluent in drainage tubes surpassing 200 mL daily, paired with triglyceride concentrations exceeding 110 mg/dL

Exclusion criteria

Patients with severe cardiac, hepatic and renal insufficiency;
Patients with a history of iohexol allergy or allergy to contrast media;
Patients who have received other interventions;
Patients with severe intestinal obstruction or intestinal perforation;
Patients who are unable to comply with the requirements of the study or are unable to complete follow-up.